Mohamed Elfil, Hanin Sabet, Abdallah Abbas, Ahmed Bayoumi, Hazem S Ghaith, Mohamed Hesham Ghoneem, Amr Shaarawy, Monsef Ibrahim Kharboush, Mohammad Aladawi, Zaid Najdawi, Chaitanya Medicherla, Daniel A Schwartz, Kelly A Hutcheson, Daniel Elefant, Gurmeen Kaur, Chirag D Gandhi, Fawaz Al-Mufti
{"title":"高压氧治疗视网膜动脉闭塞的疗效和安全性:系统回顾和荟萃分析。","authors":"Mohamed Elfil, Hanin Sabet, Abdallah Abbas, Ahmed Bayoumi, Hazem S Ghaith, Mohamed Hesham Ghoneem, Amr Shaarawy, Monsef Ibrahim Kharboush, Mohammad Aladawi, Zaid Najdawi, Chaitanya Medicherla, Daniel A Schwartz, Kelly A Hutcheson, Daniel Elefant, Gurmeen Kaur, Chirag D Gandhi, Fawaz Al-Mufti","doi":"10.1017/cjn.2025.10364","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Retinal artery occlusion (RAO) is a vision-threatening condition with limited therapeutic options. Hyperbaric oxygen therapy (HBOT) has emerged as a potential treatment to enhance retinal oxygenation and salvage ischemic tissue, though its efficacy and safety remain debated.</p><p><strong>Methods: </strong>We followed the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines and the Cochrane Handbook for Systematic Reviews of Interventions. Databases were searched through November 2024 for studies comparing HBOT with control in RAO patients. Risk of bias was assessed using the Newcastle-Ottawa Scale. Meta-analyses evaluated visual acuity (VA), best-corrected visual acuity (BCVA) and adverse events (AEs).</p><p><strong>Results: </strong>Nine studies with 499 patients (286 HBOT, 213 non-HBOT) met the inclusion criteria. HBOT was associated with improved BCVA (MD: -0.63, 95% CI: [-1.14, -0.12], <i>p</i> = 0.01) after sensitivity analysis. No significant differences were observed in uncorrected VA or lines of improvement. AEs included seizures (1.47%), ear barotrauma (1.65%) and epistaxis (0.83%) in the HBOT group. Notably, HBOT was associated with lower rates of neovascular glaucoma (7.89% vs. 15.79%) and stroke (4.3% vs. 16.6%) compared to controls.</p><p><strong>Conclusions: </strong>HBOT demonstrates potential for improved visual outcomes in RAO patients, particularly BCVA, with a generally favorable safety profile. However, heterogeneity among studies and limited sample sizes highlight the need for robust prospective trials to clarify its role in RAO management.</p>","PeriodicalId":56134,"journal":{"name":"Canadian Journal of Neurological Sciences","volume":" ","pages":"1-10"},"PeriodicalIF":2.2000,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy and Safety of Hyperbaric Oxygen Therapy for Retinal Artery Occlusion: A Systematic Review and Meta-Analysis.\",\"authors\":\"Mohamed Elfil, Hanin Sabet, Abdallah Abbas, Ahmed Bayoumi, Hazem S Ghaith, Mohamed Hesham Ghoneem, Amr Shaarawy, Monsef Ibrahim Kharboush, Mohammad Aladawi, Zaid Najdawi, Chaitanya Medicherla, Daniel A Schwartz, Kelly A Hutcheson, Daniel Elefant, Gurmeen Kaur, Chirag D Gandhi, Fawaz Al-Mufti\",\"doi\":\"10.1017/cjn.2025.10364\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Retinal artery occlusion (RAO) is a vision-threatening condition with limited therapeutic options. Hyperbaric oxygen therapy (HBOT) has emerged as a potential treatment to enhance retinal oxygenation and salvage ischemic tissue, though its efficacy and safety remain debated.</p><p><strong>Methods: </strong>We followed the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines and the Cochrane Handbook for Systematic Reviews of Interventions. Databases were searched through November 2024 for studies comparing HBOT with control in RAO patients. Risk of bias was assessed using the Newcastle-Ottawa Scale. Meta-analyses evaluated visual acuity (VA), best-corrected visual acuity (BCVA) and adverse events (AEs).</p><p><strong>Results: </strong>Nine studies with 499 patients (286 HBOT, 213 non-HBOT) met the inclusion criteria. HBOT was associated with improved BCVA (MD: -0.63, 95% CI: [-1.14, -0.12], <i>p</i> = 0.01) after sensitivity analysis. No significant differences were observed in uncorrected VA or lines of improvement. AEs included seizures (1.47%), ear barotrauma (1.65%) and epistaxis (0.83%) in the HBOT group. Notably, HBOT was associated with lower rates of neovascular glaucoma (7.89% vs. 15.79%) and stroke (4.3% vs. 16.6%) compared to controls.</p><p><strong>Conclusions: </strong>HBOT demonstrates potential for improved visual outcomes in RAO patients, particularly BCVA, with a generally favorable safety profile. However, heterogeneity among studies and limited sample sizes highlight the need for robust prospective trials to clarify its role in RAO management.</p>\",\"PeriodicalId\":56134,\"journal\":{\"name\":\"Canadian Journal of Neurological Sciences\",\"volume\":\" \",\"pages\":\"1-10\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-07-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Canadian Journal of Neurological Sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1017/cjn.2025.10364\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Journal of Neurological Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1017/cjn.2025.10364","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:视网膜动脉闭塞(RAO)是一种视力威胁疾病,治疗选择有限。高压氧治疗(HBOT)已成为一种潜在的治疗方法,可以增强视网膜氧合和挽救缺血组织,尽管其有效性和安全性仍存在争议。方法:我们遵循系统评价和荟萃分析的首选报告项目(PRISMA)指南和Cochrane干预措施系统评价手册。数据库检索到2024年11月,以比较HBOT与对照组在RAO患者中的研究。偏倚风险采用纽卡斯尔-渥太华量表进行评估。meta分析评估了视力(VA)、最佳矫正视力(BCVA)和不良事件(ae)。结果:9项研究共499例患者(286例HBOT, 213例非HBOT)符合纳入标准。敏感性分析显示,HBOT与BCVA改善相关(MD: -0.63, 95% CI: [-1.14, -0.12], p = 0.01)。在未纠正的VA或改善线中未观察到显著差异。HBOT组的ae包括癫痫发作(1.47%)、耳气压伤(1.65%)和鼻出血(0.83%)。值得注意的是,与对照组相比,HBOT与较低的新生血管性青光眼(7.89%对15.79%)和中风(4.3%对16.6%)发生率相关。结论:HBOT具有改善RAO患者视力的潜力,特别是BCVA患者,具有良好的安全性。然而,研究之间的异质性和有限的样本量突出了需要强有力的前瞻性试验来阐明其在RAO管理中的作用。
Efficacy and Safety of Hyperbaric Oxygen Therapy for Retinal Artery Occlusion: A Systematic Review and Meta-Analysis.
Background: Retinal artery occlusion (RAO) is a vision-threatening condition with limited therapeutic options. Hyperbaric oxygen therapy (HBOT) has emerged as a potential treatment to enhance retinal oxygenation and salvage ischemic tissue, though its efficacy and safety remain debated.
Methods: We followed the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines and the Cochrane Handbook for Systematic Reviews of Interventions. Databases were searched through November 2024 for studies comparing HBOT with control in RAO patients. Risk of bias was assessed using the Newcastle-Ottawa Scale. Meta-analyses evaluated visual acuity (VA), best-corrected visual acuity (BCVA) and adverse events (AEs).
Results: Nine studies with 499 patients (286 HBOT, 213 non-HBOT) met the inclusion criteria. HBOT was associated with improved BCVA (MD: -0.63, 95% CI: [-1.14, -0.12], p = 0.01) after sensitivity analysis. No significant differences were observed in uncorrected VA or lines of improvement. AEs included seizures (1.47%), ear barotrauma (1.65%) and epistaxis (0.83%) in the HBOT group. Notably, HBOT was associated with lower rates of neovascular glaucoma (7.89% vs. 15.79%) and stroke (4.3% vs. 16.6%) compared to controls.
Conclusions: HBOT demonstrates potential for improved visual outcomes in RAO patients, particularly BCVA, with a generally favorable safety profile. However, heterogeneity among studies and limited sample sizes highlight the need for robust prospective trials to clarify its role in RAO management.
期刊介绍:
Canadian Neurological Sciences Federation The Canadian Journal of Neurological Sciences is the official publication of the four member societies of the Canadian Neurological Sciences Federation -- Canadian Neurological Society (CNS), Canadian Association of Child Neurology (CACN), Canadian Neurosurgical Society (CNSS), Canadian Society of Clinical Neurophysiologists (CSCN). The Journal is a widely circulated internationally recognized medical journal that publishes peer-reviewed articles. The Journal is published in January, March, May, July, September, and November in an online only format. The first Canadian Journal of Neurological Sciences (the Journal) was published in 1974 in Winnipeg. In 1981, the Journal became the official publication of the member societies of the CNSF.